Recent clinical trials of retinal pigment epithelium gene (RPE65) supplementation therapy in Leber congenital amaurosis type 2 patients have demonstrated improvements in rod and cone function, but it may be some years before the effects of therapy on photoreceptor survival become apparent. The Rpe65-deficient dog is a very useful pre-clinical model in which to test efficacy of therapies, because the dog has a retina with a high degree of similarity to that of humans. In this study, we evaluated the effect of RPE65 gene therapy on photoreceptor survival in order to predict the potential benefit and limitations of therapy in patients. We examined the retinas of Rpe65-deficient dogs after RPE65 gene therapy to evaluate the preservation of rods and cone photoreceptor subtypes. We found that gene therapy preserves both rods and cones. While the moderate loss of rods in the Rpe65-deficient dog retina is slowed by gene therapy, S-cones are lost extensively and gene therapy can prevent that loss, although only within the treated area. Although LM-cones are not lost extensively, cone opsin mislocalization indicates that they are stressed, and this can be partially reversed by gene therapy. Our results suggest that gene therapy may be able to slow cone degeneration in patients if intervention is sufficiently early and also that it is probably important to treat the macula in order to preserve central function.
INTRODUCTION
Deficiency in the retinoid isomerase, retinal pigment epithelium (RPE)65, causes a form of retinal dystrophy, known as Leber congenital amaurosis type 2 (LCA2). RPE65 is essential for the recycling of the rod photoreceptor chromophore, 11-cis-retinal, and catalyzes the conversion of all-trans retinyl esters to 11-cis-retinol within the RPE. [1] [2] [3] [4] [5] Despite growing evidence for alternative or supplemental pathways for supplying cones with chromophore, [6] [7] [8] [9] RPE65-mediated chromophore recycling is also vital for cone photoreceptor function. [10] [11] [12] [13] [14] The disease results in early onset visual deficits. LCA2 patients have a significant reduction in rod sensitivity that is present from birth. 15, 16 Night blindness with absent or severely diminished rod responses is described as a very early phenomenon. [15] [16] [17] The majority of young patients retain some bright-light vision and cone responses are detectable by electroretinography within the first one to two decades of life. [15] [16] [17] [18] [19] Complete vision loss typically progresses by the third decade of life. Morphologically, while the retina is well preserved until the second decade, the disorder commonly results in near complete loss of rods and cones by the end of the third decade of life. 19, 20 The apparent temporal discrepancy between photoreceptor dysfunction and degeneration provides a window for therapeutic intervention.
Rods and cones appear to be lost at different rates and there appears to be variation in the speed of photoreceptor degeneration in different regions and between patients. [20] [21] [22] [23] Rods and cones may compete for available chromophore; 24 therefore, it is possible that RPE65 deficiency affects photoreceptors to a greater extent in regions of high density, such as the macula. Although there is limited histological information from patients, high-resolution optical coherence tomography has been used to evaluate the retinal thickness of RPE65 patients. There is variation in photoreceptor degeneration and dysfunction between patients. This may be due to multiple factors, including variation in RPE65 mutations (some of which might result in residual enzyme activity), [25] [26] [27] [28] environmental factors and background genetics. Many patients appear to suffer some early foveal cone loss, 19, 29 although subsequent foveal degeneration progresses slowly; 19, 30 many patients still retain foveal islands late in disease, 21 ,26,31 whereas other do not. It appears that in some patients, S-cone function is lost early in disease; 28 one study attributed residual cone function to LM-cone function. 19 From these studies there is a suggestion that S-cones are most susceptible to degeneration, followed by rods, then LM-cones, the survival of which result in preservation of foveal islands. However, this has not been definitively proven due to the lack of high-quality histological data at appropriate stages from LCA2 patients. As cone photoreceptors are essential for fine visual acuity, prevention of cone degeneration is therefore the ultimate goal for therapeutic intervention in LCA2 patients.
Recent phase I/II gene therapy clinical trials in LCA2 patients have demonstrated that subretinal delivery of AAV2-mediated RPE65 gene therapy is safe and can provide rescue of rod- [31] [32] [33] [34] [35] [36] [37] [38] and cone-mediated 31 vision in patients with advanced disease at least in the short-term. The assessment of rod and cone survival will require long-term follow-up in the small numbers of subjects treated to date. Detailed information on the effect in animal models of gene therapy on photoreceptor survival, particularly preservation of cones, is therefore important to help predict long-term outcomes as younger patients in the earlier stages of disease are treated. It is possible that treatment outcomes may vary depending on the location of treatment in relation to the rod and cone photoreceptor density, which varies across different regions of the human retina.
Rpe65-deficient mice exhibit early loss of cone photoreceptor function and rapid cone degeneration that can be prevented only when mice are treated using gene therapy at a very young age. [39] [40] [41] However, rapid cone degeneration, a short lifespan and the absence of a distinct geographic region of high photoreceptor density make the mouse an imperfect model of human LCA2. In contrast, the dog does have regional differences in rod and cone densities. 42 A naturally occurring canine model of Rpe65-deficiency has been previously described [43] [44] [45] caused by a four base-pair deletion in Rpe65. [46] [47] [48] Both rod and cone dysfunction occur early in life, but rod degeneration is slow. [48] [49] [50] [51] Surprisingly, young Rpe65-deficient dogs have not been shown to undergo cone degeneration up to the age of 17 months, 52 despite evidence of early and persistent cone dysfunction, as determined by nearcomplete absence of full-field light-adapted cone flicker electroretinogram (ERG) responses in young adult dogs. 47, 48, 53, 54 However, RPE65 gene therapy consistently rescues both rod and cone function in the young Rpe65-deficient dog. 47, 48, 54, 55 This indicates that there is a therapeutic window during which time dysfunctional cones can be rescued before degeneration. These previous studies assessed cone function by analysis of full-field white-light ERGs and were therefore not able to evaluate in detail the regional effects of gene therapy, nor the survival and improvement in function of cone subtypes.
In this study, we provide, for the first time, a detailed assessment of the effect of RPE65 gene therapy on rod and cone photoreceptor survival within different regions of the Rpe65-deficient canine retina.
RESULTS
Rods and cones are lost with age in the Rpe65-deficient dog To evaluate the progression of photoreceptor degeneration with age in the Rpe65-deficient dog, we examined three matched retinal regions (area centralis (AC), visual streak (VS) and superior peripheral retina-see Supplementary Figure 1 ) in two eyes from young dogs (mean age 3.3 months) and two eyes from older dogs (mean age 65.5 months). Both young and old dogs had reduced or absent rod and cone ERG responses (Supplementary Table 1) . Older dogs had fewer remaining rod photoreceptors in the outer nuclear layer than younger dogs in all three retinal regions ( Figure 1a and Table 1 ). The total number of cones (human cone arrestin (CAR)-positive) was also lower in the retinas of older dogs compared with the younger dogs ( Figure 1a and Table 1) . A greater proportion of cone photoreceptors were lost in the high cone density retinal regions of the AC and the VS than the lower density region of the superior periphery (SP). There were only slightly fewer LM-opsin-positive cones in older dogs compared with the younger animals ( Figure 1b ; Table 1 ) However, LM-opsin mislocalization to the inner segment, cell body, axon and pedicle, a sign of cone 'distress', 56, 57 was observed in both young and old animals. Extensive loss of S-opsin-positive cones was observed in the older dogs compared with the younger animals ( Figure 1c and Table 1 ). S-opsin mislocalization to the inner segment was observed in the younger animals, but was difficult to identify in eyes from older animals, most likely because of the very low numbers of remaining S-opsin-positive cones and the low expression level in the remaining cells.
Rod and cone photoreceptors are preserved following gene therapy Improved rod and cone function following gene therapy was confirmed using full-field ERG analysis (Supplementary Table 1) .
To evaluate rod and cone preservation in treated and untreated retinal regions, counts of the outer nuclear layer (DAPI-stained nuclei in the outer nuclear layer) and human CAR-positive cones were performed (Figure 2 ). Rod numbers were calculated by subtracting the cone nuclei count (CAR-positive cells) in each section from the total photoreceptor count (DAPI-stained nuclei) in the outer nuclear layer. Counts are represented per 500 mm of retinal length. RPE65 immunohistochemistry was used to identify treated ( Figure 2a ) versus untreated (Figure 2b ) areas of retina. There was a significant preservation of rods in treated areas of retina (mean 1904 rods per 500 mm length) compared with untreated areas (mean 1751 rods per 500 mm length, P ¼ 0.0475; Figure 2c ). Using a mixed-effects model comparison, the effect of treatment did not vary across the three types of treated regions that were examined-AC, VS and SP; P ¼ 0.58. To illustrate further the effect of injection on rod photoreceptor preservation, individual animals were selected that had a region treated in one eye, and an equivalent untreated region in the contralateral eye (Figure 2d ). In all animals examined, injection in each of the three regions (AC, VS and SP) resulted in greater survival of rod photoreceptors than the untreated contralateral eye.
Total cone numbers, as estimated by counting of CAR-positive cell bodies, were preserved following gene therapy (Figure 2e ). The effect of treatment did not vary between AC, VS and SP (P ¼ 0.60). There were significantly more cones in treated areas (mean 194 cones per 500 mm length) than in untreated areas (mean 166 cones per 500 mm length, P ¼ 0.0008).
LM-opsin mislocalization is improved following gene therapy To examine the effect of gene therapy on LM-cone photoreceptors, LM-cone opsin-positive cones were counted in treated ( Figure 3a ) and untreated regions (Figure 3b ). We did not detect a difference in the density of LM-cones between treated and untreated areas (Figure 3c , P ¼ 0.96). To further evaluate LM-cone health, we counted the number of cones containing mislocalized LM-opsin in the inner segment, cell body, axon and pedicle in treated and untreated regions. A small proportion of LM-cones contained mislocalized opsin. LM-opsin mislocalization did not vary between different regions (P ¼ 0.87 for inner segment/cell body mislocalization, P ¼ 0.72 for axon/pedicle mislocalization). There were fewer LM-cones with mislocalized opsin in the inner segment and cell body in treated areas compared with untreated areas (Figure 3d , mean percentage of LM-cones containing mislocalized opsin treated 14.0%, untreated 18.6%; P ¼ 0.03). Treatment resulted in similar reductions in LM-opsin mislocalization to the cone axon and/or synaptic pedicle (Figure 3e ; mean percentage of LM-cones containing mislocalized opsin treated 5.2%, untreated 8.2%; P ¼ 0.0039).
S-cones are preserved by gene therapy To examine the effect of gene therapy on S-cone survival, S-cone opsin-positive outer segments were counted in treated (Figure 4a ) and untreated regions (Figure 4b ). Treated regions contained more S-opsin-positive cone outer segments than untreated regions. This effect is illustrated well by the retinal flatmount showing greater numbers of S-cones (Figure 4c ) in the treated area as determined by RPE65 immunohistochemistry of the corresponding region of the flatmounted RPE (corresponding areas determined using the distance from identifiable features, such as the optic nerve, proximity to radial incision; Figure 4d ). S-cone numbers were significantly higher in treated regions compared with untreated regions (Figure 4e ). A significant interaction was identified between treatment status and region (P ¼ 0.049). Using the post-hoc pairwise analysis, treated areas contained significantly more S-cones than untreated areas in the AC (mean treated: 25 S-cones per 500 mm length, untreated: 4 S-cones per 500 mm length; post-hoc pairwise analysis Po0.001) and VS (mean treated: 18 S-cones per 500 mm length, untreated: 5 S-cones per 500 mm length; Po0.01), but not in the nasal SP (mean treated: 14 S-cones per 500 mm length, untreated: 6 S-cones per 500 mm length; P ¼ 0.057). Comparison of the untreated areas using ANOVA showed that there was no significant difference in the survival between the three regions examined (P ¼ 0.47; Figure 4e ). Conversely, comparison of the treated areas using ANOVA showed that there was a significant difference between regions (ANOVA P ¼ 0.02). A Tukey multiple comparison analysis showed that in the injected areas, there were significantly more surviving S-cones in the AC than in the SP (P ¼ 0.002, Figure 4e ), all other comparisons were not significantly different.
We also examined S-cones as a percentage of total cones by quantifying the number of S-cone-positive outer segments as a proportion of peanut agglutinin-positive cone matrix sheaths. The effect of treatment did not vary across regions (P ¼ 0.32). Gene therapy significantly increased the percentage of S-cones as a proportion of all cones (Figure 4f ; mean S-cone percentage treated 9.8%, untreated 3.1%; Po0.0001). There were very few remaining S-cones in untreated regions, but of those that remained, a high proportion contained mislocalized S-opsin compared with treated regions (Figure 4g ). However, statistical Rods and cones are lost with age in the Rpe65-deficient dog. To confirm that rod and cone loss occurs with Rpe65-deficiency, two eyes from young (mean 3.3-months-old) and two eyes from old (mean 65.5-months-old) Rpe65-deficient dogs were examined. Total photoreceptor numbers (DAPI-stained ONL nuclei in blue) and cone numbers (CAR in red) were reduced in all three measured regions in older Rpe65-deficient dogs compared with younger dogs (a). Cones labeled with long-medium wavelength opsin (LM-opsin in red, all cone matrix sheaths labeled with PNA in green) did not appear to have significantly decreased in number in the middle-aged dog compared with the 3-month-old dog (b), although LM-cones had detectable opsin mislocalization to the inner segment, cell body, axon and pedicle in both young and old animals (white arrowheads in b). There was significant loss of S-opsin positive cones with age (c). S-opsin mislocalization was also detected in young animals (white arrowhead in c). Scale bar in a represents 50 mm for all images. DAPI, nuclear counterstain; LM-opsin, long/medium-wavelength cone opsin; S-opsin, short wavelength cone opsin; inl, inner nuclear layer; onl, outer nuclear layer; rpe, retinal pigment epithelium; tap, tapetum lucidum.
analysis was not performed due to the low numbers of surviving S-cones in untreated regions.
S-cone preservation does not extend beyond the transduced area following gene therapy To determine the extent to which S-cones were preserved outside the area of retinal transduction, we examined a border region (determined by RPE65 immunostaining in the RPE) in the superior peripheral retina ( Figure 5 ). This region was chosen as it usually contained an area of treated and untreated retina, and the distribution of cones do not normally vary along this horizontal plane (Location 2; Supplementary Figure 1A) . 42 S-cones were present within the transduced region, but there was a sharp reduction in the number of S-cones immediately outside of the transduced region (Figures 5a and e) . Quantification of S-cone density showed a greater number of surviving S-cones within the transduced region right up to the border of the transduced region, To evaluate the effect of gene therapy on rod and cone preservation, the outer nuclear layer (DAPI; blue) and CAR (red) positive cell bodies were counted from retinal sections from treated (a) and untreated (b) retinal regions. RPE65 immunohistochemistry (green) was used to confirm the treated/untreated status. Photoreceptors were significantly preserved in treated regions (c), although the difference between treated and untreated regions was small due to the slow rod degeneration seen in this model. To further examine photoreceptor preservation, individual animals were identified that had a region treated in one eye, and the same region untreated in the contralateral eye. The treated regions all had large numbers of surviving photoreceptors compared with the comparable contralateral untreated region (d). Injection preserved the number of CAR-positive cone photoreceptors (e).
then a sharp decline in S-cone density immediately outside this region (Figure 5f ). Statistical analysis using a Bayesian method of change-point analysis 58 showed that the highest probability of a change in S-cone density was found at the border of transduced and untransduced RPE (probability of 0.42, Figure 5g) ; all other regions contained a relatively equal and low probability of being the location of a change in density (probability range from 0.00-0.12).
DISCUSSION
In this study, we show that Rpe65-deficiency in the dog results in rod and cone loss, but while rods and LM-cones degenerate slowly, we show for the first time that S-cones are lost more rapidly and extensively. RPE65 gene therapy preserves S-cones, but the effect of treatment is limited to the transduced area. Rpe65-deficiency in the dog also results in extensive cone opsin mislocalization that was partially reversed in LM-cones by RPE65 gene therapy.
The human retina is rod dominant but contains an exclusively cone region known as the fovea, within which the central 100-150 mm does not contain S-cones. 59 Some patients with RPE65-deficiency have early foveal cone loss, although in many patients, foveal islands can be detected late in disease. 21, 26, 31, 60 Clinical testing has identified early loss of S-cone function in some patients, 28 with residual cone function attributed to LM-cone function. 19 Mouse cone photoreceptor development and retinal distribution is significantly different from primates. The mouse retina does not contain a cone-rich region, rather a superior distribution of LM-cones and a predominantly inferior distribution of S-cones, which comprise a significant proportion of cones. 61 S-cones in the mouse retina develop before LM-cones, 62 which is contrary to the situation in the primate fovea. 63 Significant co-expression of cone opsins also exists in the mouse retina, unlike the human or dog. 62 In mice with Rpe65-deficiency, S-cones are lost very early in disease, followed by LM-cone degeneration and subsequent rod degeneration. S-cone degeneration is complete or near-complete by 5 weeks in the Rpe65 À / À mouse, 40 5 months in the Rpe65 rd12 mouse 40 and 6 months in the Rpe65 R91W mouse, 24 whereas LMcone degeneration proceeds more slowly in all models, with complete cone loss present by 6 months in Rpe65 À / À mice. 29 Associated rod degeneration results in 6-7 remaining rows of photoreceptors by 7 months in both the Rpe65 À / À mouse 1 and the Rpe65 rd12 mouse. 64 Although not identical, the canine cone photoreceptor distribution more closely matches that of the primate, as it contains a cone-rich region known as the area centralis, with little or no co-expression of cone opsins throughout the retina. 42 S-cones in the AC represent B10-12% of cones; 42 a similar percentage of total cones to the primate parafoveal area. 59, 65 Our studies of . Peanut agglutinin (green) was used to identify all cone matrix sheaths. We did not detect an effect of treatment on LM-opsin cone numbers (c), but treatment reduced the extent of LM-opsin mislocalization to the inner segment or cell body (d) and the axon or pedicle (e). Scale bar in a represents 50 mm for all images. DAPI, nuclear counterstain; LM-opsin, long/medium-wavelength opsin; PNA, peanut agglutinin.
3.3-month-old Rpe65-deficient dogs indicate that extensive S-cone degeneration has not occurred before this age. The rate of photoreceptor degeneration is significantly slower in the dog than in mouse models, with minimal rod and no cone degeneration detected subjectively up to 17 months of age. 52 However, by 66 months (5.5 years) of age we showed quantitatively that extensive S-cone degeneration has occurred throughout the retina, whereas rods and LM-cones degenerate more slowly. This pattern of degeneration may more closely mirror the natural history of the disease seen in many LCA2 patients than currently available mouse models. Our study identified mislocalization of LM-and S-cone opsin as early as 3 months of age in untreated Rpe65-deficient dogs. Our results are in contrast to a recent study that did not identify cone opsin mislocalization up to 17 months of age in Rpe65-deficient dogs. 52 It is possible that our study was able to detect smaller amounts of mislocalized cone-opsin owing to higher primary antibody concentrations used in immunohistochemistry, or could be related to the differences in background genetics in the study populations resulting in differences in disease phenotype. In our study, RPE65 gene therapy resulted in preservation of S-cones, with very few containing mislocalized opsin, compared with a high proportion of S-cones containing mislocalized opsin in untreated areas. The degree of LM-cone opsin mislocalization was also partially reduced following gene therapy. Similar results to ours were shown in Rpe65 À / À mice using 11-cis-retinal replacement where S-cone opsin mislocalization was resolved, but LM-opsin mislocalization was only partially reversed. 12, 56, 66 This indicates that in the dog, like the mouse, 11-cis-retinal is important for LM-cone opsin trafficking. 13, 66 The failure to completely restore normal LM-opsin localization may be related to the dose of 11-cis-retinal required. 66 Although in our study, we have shown that RPE65 gene therapy was able to restore cone function, and prevent S-cone degeneration, we did not Figure 4 . S-cones are preserved following RPE65 gene-therapy. To evaluate S-cone preservation, numbers of S-cones were counted in treated and untreated retinal regions. S-cone opsin positive cones were present in all treated regions (a) but were present in significantly lower numbers in untreated regions (b). Examination of a flatmount preparation from dog 05-069 of RPE/choroid labeled with RPE65 (green; c) and retina labeled with PNA (blue) and S-opsin (red) (d) showed a sharp demarcation between treated and untreated regions. Both S-cone density (e) and the percentage of S-cones as a proportion of total cones (f) were significantly higher in treated regions compared with the counts from eyes where the same region was not treated. Mislocalization of S-opsin appeared higher in untreated regions (g) but low numbers of remaining S-cones in untreated areas precluded statistical analysis. Scale bar in a represents 50 mm for a and b, in c represents 100 mm for c and d. **Po0.01; ***Po0.001. ns, non significant; S-opsin, short-wavelength opsin; PNA, peanut agglutinin; DAPI, nuclear counterstain. measure the amount of 11-cis-retinal produced, and it is possible that insufficient 11-cis-retinal was produced to resolve opsin mislocalization fully.
Why are S-cones susceptible to degeneration, but LM-cones are resistant to degeneration in the dog? The mislocalization of opsin may contribute to the particular susceptibility of S-cones. A recent study has shown that in the Lrat À / À mouse, intracellular mislocalized LM-opsin is degraded, whereas mislocalized S-opsin is somewhat resistant to intracellular degradation, and may contribute to cell death. 67 In the Rpe65-deficient dog, S-cones degenerate to a greater extent than LM-cones and LM-and S-cone opsin is mislocalized as early as 3-months old, indicating that the Rpe65-deficient dog may have similar mechanisms for S-cone degeneration to the Rpe65-deficient mouse. Alternative non-RPE-mediated mechanisms for cone visual pigment recycling have been shown to exist in the mammalian retina (for a review, see Wang et al. 8 ). The relative contribution of the RPE and alternate visual pigment recycling pathways is unknown, although LM-cones in mice are only partially reliant on the RPE for light-sensitive visual pigment recycling. 68 However, similar studies in S-cones have not been performed. Our study suggests that in the dog, S-cones derive significant amounts of chromophore from the RPE, as Rpe65-deficiency results in S-cone opsin mislocalization and subsequent S-cone degeneration, and RPE65 gene therapy using an RPEspecific promoter can prevent S-cone degeneration. Another explanation might be that rods, LM-and S-cones compete for the small amount of residual 9-cis-retinal present in the eyes of Rpe65-deficient animals as was suggested to occur in the Rpe65 R91W mouse. 24 Oral 9-cis-retinal prevents cone degeneration in Rpe65-deficient mice 29 and intravitreally delivered 9-cis-retinal can rescue rod and cone function in Rpe65-deficient dogs. 53 Rods and LM-cones may be able to more efficiently entrap the residual retinoid, preventing S-cones from acquiring retinoid, and causing S-cone degeneration. A similar finding was identified in the Rpe65 R91W hypomorphic mouse model of Rpe65 deficiency. 69 This hypothesis is supported in part by our finding that older . S-cone preservation does not extend significantly beyond the treated area. To evaluate the spread of gene therapy effect beyond the detectable treated area, the interface regions between treated and untreated retina were quantified for S-cone numbers. Representative lowpower images show that there was a correlation between the treated RPE65 immunoreactivity and s-cone preservation (a-c). Treated regions had extensive S-cone preservation (d), whereas the untreated regions immediately adjacent showed very limited S-cone survival (e). Graphical representation of the interface region of all eyes showed a significant reduction in S-cone survival within 225 mm of the border of injection (f). The highest probability of a change-point was at the border of the transduced and untransduced RPE (g). Scale bar in a represents 100 mm for images a-c, scale bar in d represents 50 mm for images d and e. DAPI, nuclear counterstain, S-opsin; short wavelength opsin.
Rpe65-deficient dogs have a greater proportional loss of S-cones in the high-density AC and VS than in the less dense area of the nasal SP, although further experiments with larger numbers of eyes would be required to confirm this. We did not find significant regional differences in the effect of gene therapy on the total number of CAR-positive cones, although there appeared to be greater preservation with gene therapy in the AC than in the retinal periphery. This slight difference in total cone numbers may be the result of the significant effect of gene therapy on S-cone survival and the naturally higher density of S-cones found within the normal canine AC. 42 This is further supported by the significant cone degeneration we show in untreated older animals (65 months of age) within all regions examined that can be attributed mostly to a profound S-cone degeneration. We found no regional effects of gene therapy on S-cone preservation, despite investigating the effects in regions of the retina with a variety of rod and cone densities. Although a greater number of S-cones survived in the treated AC, when S-cones were represented as a proportion of total cones, a similar percentage was preserved in all regions of the retina, and the percentage approached normal values for the dog retina (9.9-18.3%). 42 This indicates that the amount of RPE65 produced following gene therapy is sufficient to preserve S-cones even in the highest density of rods and cones in the canine AC. Further clinical studies will be necessary to evaluate the dose of RPE65 required to preserve cones in the cone-only fovea. In our study, S-cone preservation was only present within the treated area, confirming previous studies showing that 11-cis-retinal does not diffuse extensively outside the treated area. 48 S-cones in the dogs treated in this study were preserved, but the S-cone numbers detected in treated areas were lower than those seen in untreated 3-month-old dogs. This may reflect the variation in age at injection (range 4.6-25.2 months of age) resulting in S-cone degeneration before injection, or the possibility that gene therapy only slows the rate of degeneration. Although there was a variation in the age at injection within our studies, the numbers of eyes available for this study precluded evaluation of the effect of age at injection on cone preservation, as there were significant potential confounding variables including the duration of treatment and the variability in the location of the injection in relation to areas of differing cone density. However, we speculate that early intervention is likely to have a greater effect on cone health in patients, as we show here that there is a profound loss of S-cones over time.
Differences in the rate of disease progression between humans and dogs with RPE65-deficiency may mean that effective therapy is more challenging in humans. Compared with dogs, which have very slow rod degeneration, early intervention will be even more important in LCA2 patients, owing to early and significant rod degeneration, 21, 26 which may contribute to cone death, perhaps related to deficiency of rod-derived cone viability factor. 70 It has yet to be proven whether S-cones are more susceptible to degeneration in people with RPE65-deficiency, and to what extent cones in the human retina are dependent on RPE65. Hence, it will be important to evaluate the effect of gene therapy on cone subtypes in younger patients enrolled in the current trials. Our evaluation of S-cone rescue in the dog model of RPE65-deficiency supports the idea that early intervention in patients is important to prevent S-cone degeneration, and that, owing to the restriction of the treatment effect to the transduced area, the fovea and perifoveal areas should be targeted in order to achieve the greatest degree of cone preservation.
MATERIALS AND METHODS Subjects
Rpe65-deficient crossbred dogs (n ¼ 12 dogs, 19 eyes) were used from a colony housed at Michigan State University Comparative Ophthalmology Laboratory. Animal care and use was in compliance with the Association for Research in Vision and Ophthalmology statement for the Use of Animals in Ophthalmic and Vision Research and all procedures were performed with approval by Michigan State University's Institutional Animal Care and Use Committee. Animals were housed on a 12 h light:dark cycle, and all tissues were harvested in the light. Table 2 outlines the ages and numbers of untreated (n ¼ 4 dogs, 4 eyes) and treated (n ¼ 8 dogs, 15 eyes) animals used in the study. Eyes from untreated animals were used to examine the extent of rod and cone photoreceptor degeneration over time; eyes from treated animals were used to examine the effects of gene therapy on rod and cone photoreceptor preservation. rAAV2/2 construct and subretinal injection A recombinant rAAV2/2 vector was used, containing the human RPE65 cDNA coding sequence driven by the human RPE65 promoter flanked by AAV2 ITRs encapsulated by an AAV2 capsid (rAAV.hRPE65p.hRPE65). Viral vector was produced by Targeted Genetics (Seattle, WA, USA), with the use of a B50 packaging cell line. 71 The rAAV titers were determined by dot blot, generating vector concentrations of between 1 Â 10 11 and 1 Â 10 12 viral genomes ml À 1 . Subretinal injections and animal treatment in the postoperative period were performed as previously described. 54, 72 Ophthalmic examination, fundic imaging and electroretinography
Complete ophthalmic examination including slit-lamp biomicroscopy and binocular indirect ophthalmoscopy was performed pre-injection and at regular intervals following injection. Wide-angle digital fundus images were captured pre-injection, immediately following injection and 3-4 months following injection (RetCam II, Clarity Medical Systems, Pleasanton, CA, USA). All eyes had complete retinal reattachment by 1 week following injection. Analysis of fundus images allowed a calculation of the retinal tapetal area and injected area proportion to be estimated as previously described. 54 Analysis of photographs taken 3-4 months following injection showed that a mean of 47.7% (±0.03% s.e.m.) of the tapetal RPE65 gene therapy slows cone loss FM Mowat et al area of retina was treated. To confirm rescue of rod and cone function, rod and cone ERG recordings were performed pre-injection, at 2, 4 and 9-12 months following injection as previously described. 54 Rod responses were assessed using the dark-adapted b-wave amplitude at 0.0 log cdS m À 2 , cone responses were assessed using the amplitude of the light-adapted 33 Hz flicker.
Tissue processing/sectioning
Following euthanasia by barbiturate overdose (Fatal Plus, Vortech Pharmaceuticals, Dearborn, MI, USA), eyes were enucleated. Slits in the pars plana were made and B0.5 ml of 4% paraformaldehyde fixative (paraformaldehyde powder 95% (Sigma-Aldrich, St Louis, MO, USA) in phosphate buffered saline (PBS) pH 7.4) was injected intravitreally. Eyes were placed in 4% paraformaldehyde for 4 h on ice, the anterior segment was removed and eyecups were washed in PBS (0.14 M NaCl, 2.7 mM KCl, 10.1 mM Na 2 HPO4, 1.8 mM KH 2 PO4 pH 7.4) and placed in 30% sucrose solution in PBS overnight at 4 1C. Eyecups were washed in PBS and embedded in optimal cutting temperature medium (TissueTek OCT, Electron Microscopy Sciences, Hatfield, PA, USA) and frozen. Eyes were stored at À 20 1C until sectioning. Fourteen micrometer sagittal retinal cryosections were collected using a cryomicrotome (Leica CM3050-S, Leica Microsystems, Buffalo Grove, IL, USA) onto poly-L-lysine coated glass slides (Electron Microscopy Sciences, Hatfield, MO, USA). Sections were taken in the horizontal plane starting at the optic nerve and moving superiorly. Sections from two areas of the eye were evaluated. In the first area, sections were taken beginning 250 mm superior to the termination of the optic nerve head, and encompassed the VS and AC (location 1; Supplementary Figures 1A and B) . In the second area, sections were taken beginning 4 mm superior to the termination of the optic nerve head, and encompassed the superior peripheral retina (location 2; Supplementary  Figures 1A and B) . Three sections 140 mm apart were collected from each area onto each slide for analysis. Retinal and RPE flatmounts were prepared using the same fixation regime. Radial incisions were made through the posterior portion of the globe and the retinal and RPE/choroid were separated. The flatmounted retina and RPE/choroid were washed in PBS before performing immunohistochemistry.
Immunohistochemistry
All immunohistochemical staining was performed using the same reagents and basic protocol. Slides were dried for 20 min, rehydrated in PBS for 20 min, then blocked for 1 h at room temperature using a solution of PBS containing 0.1% Triton X-100 (Sigma-Aldrich) and 10% normal horse serum (Sigma-Aldrich). Primary and secondary antibody staining was performed in the same blocking solution; antibody concentrations used for section immunohistochemistry are outlined in Supplementary Table 2. 73 Primary antibodies were incubated overnight at 4 1C, secondary antibodies for 2 h at room temperature. Retinal and RPE flatmounts were blocked overnight in PBS containing 0.05% Triton X-100. Primary antibodies were incubated for 2 days, agitated at room temperature (RPE65 1:1000; PNA 1: 1000; S-opsin 1:2000); secondary antibodies were incubated agitated for 16 h at room temperature in solution (streptavadin-488 1:1000; anti-rabbit 546 1:1000). Slides were mounted using antifade fluorescent mounting medium (Dako North America Inc., Carpinteria, CA, USA) and glass coverslips (Electron Microscopy Sciences, Hatfield, MO, USA) and stored at 4 1C in the dark until imaging.
Within each eye, the three regions (AC, VS and nasal SP) were defined as treated or untreated based on visualization of the RPE65 signal positivity on immunohistochemistry. Supplementary Figure 1 demonstrates the three regions examined. The AC, VS and SP include high, medium and lower density of cone photoreceptors, respectively (Supplementary Figures 1A and B) . Injections were typically confined to the AC (Supplementary Figure 1C) , VS (Supplementary Figure 1D) or SP (Supplementary Figure 1E) , although some injections covered more than one region. Immunohistochemistry was performed on serial sections of all eyes. One eye (06-086 OS) had very weak antibody staining for all antibodies tested that was likely due to inadequate fixation. As this was likely to result in very inaccurate quantification, the eye was excluded from further analysis. Of the 15 eyes, nine contained an injected AC, six contained an injected VS and eight contained an injected SP.
Regional evaluation of rod and cone photoreceptor density Slides were imaged using a fluorescent microscope (Nikon Eclipse 80i, Nikon Instruments Inc., Melville, NY, USA) using commercial image capture software (MetaVue, Molecular Devices, Sunnyvale, CA, USA) at Â 40 magnification. Three consecutive images were taken from the three regions of interest (AC, nasal VS and nasal SP), spanning a region measuring 337.5 mm. The AC and VS were imaged on the horizontal section taken at location 1 (starting 250 mm superior to the optic nerve). The approximate region of the AC was imaged beginning B1450 mm temporal to the central meridian of the eye (identified by presence of the large dorsal venule present in most dogs). The location of this region was selected based on a previous study showing the mean location of the AC in the dog. 42 The nasal VS was imaged beginning 1450 mm nasal to the central meridian of the eye. The nasal SP was imaged on the horizontal section taken at location 2 (starting 4 mm superior to the optic nerve). The region was imaged beginning B1900 mm nasal to the central meridian of the eye. Image analysis was done in a masked fashion. Masking was performed by removal of all RPE65 immunostaining information from images. Eyes were assigned a random number using an online randomizer program (www.randomizer.org). Manual counts were made of total photoreceptors (DAPI-positive nuclei within the outer nuclear layer), total cones (CAR-positive cone cell bodies), LM-cones (LM-opsin-positive outer segments) and percentage (LM-opsin-positive outer segments as a percentage of PNA-positive cone matrix sheaths), S-cone density (S-opsin-positive outer segments) and percentage (S-opsin-positive outer segments as a percentage of PNA positive cone matrix sheaths). The proportion of cones with mislocalized LM-and S-opsin were also counted; LM-opsin mislocalization was separated into detectable mislocalization to the inner segment and cell body, or axon and synaptic pedicle. All manual counting was performed using an open-source image analysis program (ImageJ, US National Institutes of Health, Bethesda, MD, USA). The results of counting provided quantification of three regions, 140 mm apart for each of the three areas (AC, VS and nasal SP). Rod number was calculated by subtracting the cone numbers from the total numbers of photoreceptors, methodology was validated using rhodopsin staining (Supplementary Figure 2A) and resulted in slight over-estimation of rod numbers, (Supplementary Figure 2B) although the different regions did not have significantly different correlations (Supplementary Figure 2C) . Rod and cone photoreceptor numbers were represented as number of cells per 500 mm length of retina. Representative images of immunohistochemistry staining were taken using a confocal microscope (Olympus FluoView 1000 confocal, Center Valley, PA, USA).
Evaluation of the spread of effect beyond the transduced area
To examine the spread of treatment effect beyond the transduced area, each border of injection (nasal and temporal) was examined using the SP section (location 2). The superior peripheral retina was selected as it consistently contained a treated region in all eyes, and contained a relatively stable number of cones, 42 making interpretation of the difference between treated and untreated regions more straightforward. The number of surviving S-cones (using S-opsin immunohistochemistry) was counted in Â 20 magnification high-power fields encompassing 1350 mm within the transduced area, and 1350 mm outside the transduced area. Three sections per eye were examined. The transduced area was positively identified using RPE65 immunohistochemistry.
Statistical analysis
The main fixed effects of interest were RPE65 gene therapy treatment, region, and the interaction between treatment and region. The purpose of including the interaction was to test for region-specific treatment effects (that is, whether the effect of treatment was different in the AC, VS or peripheral retina). Random effects included variation related to different dogs, different eyes from the same dog, and different regions within the same eye. The residual term represented variation between replicate observations sampled from the same region. Linear mixed-effects models accounting for these fixed and random effects were estimated using the nlme package 74 for R (R version 2.12.2; R Foundation for Statistical Computing, Vienna, Austria), 75 which is an open-source statistical program. Likelihood ratio tests were used to determine whether the effect of treatment was different between regions of the retina. Each of these tests compared two nested mixed-effects models: one with and one without the interaction effect. If this test was significant, it was concluded that the effect of treatment was significantly different in different regions of the retina (AC, VS and peripheral retina). A subsequent post-hoc pairwise comparison was then performed on each individual region to determine the effect of treatment. If the likelihood ratio test examining the interaction between treatment and region was not significant, it was concluded that the effect of treatment did not vary between regions. The effect of treatment was then examined with an ANOVA summary of the mixed effects model without the interaction effect (that is, containing just the main effects for region and gene therapy). Significant effects were interpreted by summarizing the means of the fitted values predicted by the model. Example codes and raw data source files are provided in Supplementary Information. To evaluate the overall region effect within treated or untreated regions (AC, VS and SP), ANOVA was performed using Tukey's multiple comparison tests where necessary.
Effects were considered significant if Po0.05. In all figures, graphs represent mean ± s.e.m.
To examine the possible spread of injection effect beyond the transduced area, a Bayesian method of change-point analysis was applied to the data generated from S-cone counting at the border of the treated area in the superior peripheral retina. 76 The probability that each location inside or outside the transduced area was a change-point from high s-cone density to low s-cone density was calculated. The bcp package for R 58 was used for this analysis.
